NEW DELHI, March 13, 2026 /PRNewswire/ -- According to the latest research study published by Vyansa Intelligence, the Cardiovascular Devices Market in the United States is projected to grow at a CAGR of around 9.35% during 2026–2032. The market expansion is primarily attributed to the increasing prevalence of cardiovascular diseases, rapid technological advancements in minimally invasive cardiac procedures, and the growing adoption of advanced diagnostic and therapeutic cardiovascular devices across healthcare facilities in the country.

United States Cardiovascular Devices Market Key Takeaways
Major Drivers Supporting the Demand for Cardiovascular Devices Across the United States
Cardiovascular diseases remain one of the leading causes of mortality and morbidity in the United States. Conditions such as coronary artery disease, cardiac arrhythmia, and heart failure affect millions of individuals across the country. The growing prevalence of lifestyle-related risk factors, including obesity, diabetes, sedentary lifestyles, and hypertension, continues to increase the overall cardiovascular disease burden. As a result, healthcare providers are increasingly relying on advanced cardiovascular diagnostic and therapeutic devices to support early detection, accurate diagnosis, and effective treatment.
Technological innovation is playing a significant role in transforming cardiovascular treatment approaches across the United States. The growing adoption of minimally invasive and transcatheter procedures enables physicians to treat complex cardiovascular conditions with reduced surgical trauma, shorter hospital stays, and improved patient recovery outcomes. Technologies such as transcatheter heart valves, catheter-based interventions, and image-guided cardiac procedures are gradually replacing conventional open-heart surgeries in several clinical applications. Consequently, medical device manufacturers continue to invest in research and development to enhance device performance and procedural efficiency.
The integration of artificial intelligence, machine learning, and wearable monitoring technologies is further expanding the capabilities of cardiovascular care. AI-powered diagnostic tools are improving the accuracy of cardiac imaging analysis and risk assessment, while wearable cardiovascular monitoring devices allow continuous tracking of heart rhythms and vital parameters. These innovations support the growing shift toward preventive healthcare and remote patient monitoring, thereby contributing to broader adoption of cardiovascular devices across clinical and home care settings.
Key Industry Constraint Limiting Market Growth
Despite ongoing technological advancements, the high cost associated with advanced cardiovascular devices and procedures remains a key challenge for the market. Technologies such as robotic-assisted cardiac surgery systems, implantable cardiac devices, and transcatheter treatment solutions often require substantial capital investment for hospitals and healthcare institutions. Additionally, regulatory approval requirements and stringent quality standards can increase product development timelines and manufacturing costs, which may limit the adoption of certain advanced cardiovascular technologies in some healthcare settings.
View Full Report and request to get the sample pages at:
https://www.vyansaintelligence.com/industry-report/united-states-cardiovascular-devices-market-analysis
Market Analysis by Device Type and End Users
By device type, therapeutic and surgical cardiovascular devices are expected to dominate the United States cardiovascular devices market, accounting for around 75% of the total share. These devices play a crucial role in the treatment of cardiovascular conditions such as coronary artery disease, heart failure, and cardiac arrhythmias. The increasing number of interventional cardiology procedures, along with the growing adoption of implantable cardiac devices and minimally invasive treatment solutions, continues to drive demand for therapeutic cardiovascular technologies across the country.
By end user, hospitals are expected to lead the market, capturing approximately 60% of the total share. Hospitals serve as the primary centers for complex cardiovascular procedures, including cardiac catheterization, heart valve interventions, and surgical treatments. Their access to advanced imaging systems, specialized cardiac care units, and highly skilled healthcare professionals enables them to manage a wide range of cardiovascular conditions effectively. Consequently, the concentration of advanced medical infrastructure within hospitals continues to strengthen their dominant position in the cardiovascular devices market.
View Full Report (All Data, In One Place):
https://www.vyansaintelligence.com/industry-report/united-states-cardiovascular-devices-market-analysis (Explore in-depth analyses, technological trends, and investment patterns.)
Major Cardiovascular Device Companies in the United States
Key companies contributing to innovation and competition in the market include:
United States Cardiovascular Devices Market Scope
By Device Type: Diagnostic and Monitoring, Therapeutic and Surgical
By Technology: Minimally Invasive and Transcatheter Technologies, Wearable Devices, Artificial Intelligence and Machine Learning, Robotic-Assisted Surgery
By Application: Coronary Artery Disease, Cardiac Arrhythmia, Heart Failure, Others
By End Users: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Care Settings
Browse More Reports on Medical Devices
France Neurodegenerative Disease Devices Market: Neurodegenerative disease devices market in France is estimated at USD 1.5 billion and is expected to grow to USD 2.5 billion by 2032. Moreover, the market is projected to register a CAGR of around 7.57% during 2026-32.
Germany Neurodegenerative Disease Devices Market: Neurodegenerative disease devices market in Germany is estimated at USD 1.74 billion and is expected to grow to USD 2.63 billion by 2032. Moreover, the market is projected to register a CAGR of around 6.08% during 2026-32.
US Wearable Medical Devices Market: Wearable medical devices market in the US is estimated at USD 12.02 billion in 2025 and is expected to grow to USD 36.93 billion by 2032. Moreover, the market is projected to register a CAGR of around 17.39% during 2026-32.
India Diabetes Monitoring Devices Market: Diabetes monitoring devices market in India is estimated at USD 2 billion in 2025 and is expected to grow to USD 2.8 billion by 2032. Also, the market is projected to register a CAGR of around 4.92% during 2026-32.
About Vyansa Intelligence
Vyansa Intelligence is a global market research and consulting firm dedicated to delivering strategic insights across high-growth and emerging industries worldwide. Our comprehensive research reports provide data-driven analysis of market trends, competitive landscapes, technological innovations, and regulatory developments shaping the global business environment. Supported by robust research methodologies, advanced forecasting models, and carefully validated primary and secondary data sources, Vyansa Intelligence empowers corporations, investors, and decision-makers to identify emerging opportunities, manage potential risks, and develop well-informed long-term strategies. We remain committed to delivering actionable market intelligence that supports sustainable business growth and strengthens competitive positioning in an increasingly dynamic marketplace.
Contact Us:
Office: Office No.110, H-159, Sector 63, Noida, Uttar Pradesh - 201301, India
Contact No: +91 7065555003
Email: sales@vyansaintelligence.com
Website: vyansaintelligence.com
Logo: https://mma.prnewswire.com/media/2929228/Vyansa_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/united-states-cardiovascular-devices-market-to-reach-usd-41-29-billion-by-2032--says-vyansa-intelligence-302712391.html

Bachem hat für das Geschäftsjahr 2025 robuste Zahlen vorgelegt und die durchschnittlichen Analystenschätzungen beim Umsatz wie beim Ergebnis übertroffen. Der Pharmazulieferer setzte 695,1 Millionen Franken um, ein Plus von 14,8 Prozent gegenüber dem Vorjahr; in Lokalwährungen lag das Wachstum sogar bei 19,2 Prozent. Im ersten Halbjahr war das Unternehmen in Lokalwährungen noch um 34 Prozent gewachsen. Unter dem Strich erzielte Bachem einen Reingewinn von 148,8 Millionen Franken und damit knapp 24 Prozent mehr als 2024. Damit lag das Unternehmen rund 30 Millionen Franken über der Konsensschätzung.
Auch auf operativer Ebene legte Bachem zu. Der EBITDA stieg um 21,8 Prozent auf 214,7 Millionen Franken, die Marge verbesserte sich um 1,8 Prozentpunkte auf 30,9 Prozent. Darin enthalten ist allerdings ein positiver Sondereffekt von 16,1 Millionen Franken aus der Standortentwicklung im Sisslerfeld sowie dem Verkauf eines Gebäudes in den USA. Bereinigt lag die EBITDA-Marge bei 28,6 Prozent und damit ungefähr auf Höhe der Markterwartungen. Aktionäre sollen an der Entwicklung teilhaben: Die Divende soll von 0,85 auf 0,90 Franken je Aktie erhöht werden.
Für Gesprächsstoff sorgt der Ausblick. Unter der neuen CEO Anne-Kathrin Stoller rückt Bachem von der bisher kommunizierten Marke eines Umsatzes von mindestens 1 Milliarde Franken ab, die 2026 erreicht werden sollte. Im aktuellen Communiqué wird dieses Mittelfristziel nicht mehr explizit erwähnt. Stattdessen stellt das Unternehmen für das laufende Jahr ein Umsatzwachstum von 35 bis 45 Prozent in Aussicht, was einer Spanne von 938 Millionen bis 1,008 Milliarden Franken entspricht. Schafft Bachem den oberen Rand, wäre die bisherige Zielmarke zwar erreicht – die weniger pointierte Formulierung dürfte aber einige Investoren veranlassen, ihre Erwartungen zu justieren.
Operativ richtet Bachem die Organisation auf weiteres Wachstum aus. 2025 investierte der Konzern 332,6 Millionen Franken über alle Standorte hinweg; im laufenden Jahr sollen die Investitionen auf über 400 Millionen Franken steigen. Hintergrund sind unter anderem mehrere Grossaufträge von Herstellern der stark nachgefragten Medikamenten zur Gewichtsreduktion. Gleichzeitig treibt Bachem den Ausbau neuer Kapazitäten voran: Die erste Bauetappe des Gebäudes K wurde Ende 2025 von der Aufsichtsbehörde Swissmedic inspiziert und freigegeben. Das Unternehmen, das Peptid-basierte Wirkstoffe für Indikationen wie Krebs, Diabetes und Fettleibigkeit liefert und parallel ein Standbein im Bereich Oligonukleotide aufbaut, setzt damit klar auf steigende Nachfrage – auch wenn es bei der kommunikativen Zuspitzung seiner Umsatzziele zurückhaltender geworden ist.